Utah Medical Products Inc. (UTMD) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q1 23	—	$1.16	—	—	$12.5M	—
Q4 22	—	$1.25	—	—	$13.6M	—
Q3 22	—	$1.18	—	—	$13M	—
Q2 22	—	$1.12	—	—	$13.4M	—
Q1 22	—	$0.96	—	—	$12.3M	—
Q4 21	—	$1.13	—	—	$12.9M	—
Q3 21	—	$1.15	—	—	$12.6M	—
Q2 21	—	$1.04	—	—	$12.6M	—
Q1 21	—	$0.83	—	—	$11M	—
Q4 20	—	$0.93	—	—	$12M	—
Q3 20	—	$0.8	—	—	$10.5M	—
Q2 20	—	$0.42	—	—	$8.8M	—
Q1 14	$0.79	$0.72	-8.9%	—	$9.8M	—
Q4 13	$0.64	$0.92	+43.8%	—	$10.1M	—
Q3 13	$0.69	$0.68	-1.4%	—	$10M	—
Q2 13	$0.62	$0.7	+12.9%	—	$10M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$3.54	—	—	$38.5M	—
FY24	—	$4.16	—	—	$40.9M	—
FY23	—	$4.58	—	—	$50.2M	—
FY22	—	$5.69	—	—	$52.3M	—
FY21

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$39.3M	$41.4M	$42M	$46.9M	$42.2M	$49.1M	$52.3M	$50.2M	$40.9M	$38.5M
YoY change	-2.14%	+5.38%	+1.41%	+11.7%	-10.1%	+16.3%	+6.58%	-3.93%	-18.6%	-5.83%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	39.3M	41.4M	42M	46.9M	42.2M	49.1M	52.3M	50.2M	40.9M	38.5M
Cost of revenue	15.6M	15M	15.7M	17.4M	16.6M	18.1M	20.1M	20.2M	16.8M	16.5M
Gross profit	23.7M	26.4M	26.3M	29.5M	25.5M	30.9M	32.2M	30M	24.1M	22M
Gross margin	60.3%	63.7%	62.6%	62.8%	60.6%	63%	61.6%	59.8%	59%	57.1%
Research & development	475K	447K	454K	483K	486K	526K	493K	560K	813K	668K
Selling, general & administrative	7M	6.9M	7.2M	11.4M	11.4M	11.5M	11.9M	12.7M	9.7M	9.9M
Operating expenses	7.5M	7.4M	7.6M	11.8M	11.8M	12M	12.4M	13.3M	10.5M	10.6M
Operating income	16.2M	19M	18.7M	17.6M	13.7M	18.9M	19.8M	16.8M	13.6M	11.4M
Operating margin	41.2%	45.9%	44.5%	37.6%	32.5%	38.5%	37.9%	33.4%	33.2%	29.6%
Non-operating income, net	235K	71K	762K	252K	132K	181K	869K	3.3M	3.2M	2.7M
Pretax income	16.4M	19.1M	19.5M	17.9M	13.8M	19.1M	20.7M	20.1M	16.8M	14.1M
Income tax	4.3M	10.6M	904K	3.2M	3M	4.3M	4.2M	3.5M	2.9M	2.8M
Net income	12.1M	8.5M	18.6M	14.7M	10.8M	14.8M	16.5M	16.6M	13.9M	11.3M
Net margin	30.9%	20.5%	44.2%	31.4%	25.6%	30.1%	31.5%	33.1%	33.9%	29.3%
EBITDA	19M	21.8M	21.4M	24.3M	20.8M	26M	26.2M	20.1M	13.1M	11.6M
EPS	3.22	2.29	4.99	3.94	2.96	4.15	5.69	4.58	4.16	3.54
Diluted EPS	3.22	2.28	4.95	3.94	2.94	4.04	4.52	4.57	3.96	3.48

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	12.5M	12.3M	11.3M	10.4M	10M	9.2M	9.7M	10M	9.8M	9M	8.7M	8.5M
Cost of revenue	5.1M	5.2M	4.6M	4.1M	4.2M	3.8M	4.2M	4.4M	4.2M	3.8M	3.4M	3.8M
Gross profit	7.4M	7.1M	6.8M	6.3M	5.8M	5.3M	5.5M	5.6M	5.6M	5.3M	5.3M	4.8M
Gross margin	58.8%	57.6%	59.7%	60.1%	58%	58.1%	57%	56.2%	57.1%	58.2%	60.6%	55.8%
Research & development	138K	146K	266K	255K	172K	121K	155K	135K	167K	212K	154K	154K
Selling, general & administrative	3.3M	3M	1.4M	2.6M	2.3M	2.3M	1.4M	2.3M	2.8M	2.6M	1.7M	2M
Operating expenses	3.4M	3.2M	1.6M	2.8M	2.5M	2.4M	1.6M	2.4M	3M	2.8M	1.8M	2.1M
Operating income	4M	3.9M	4.6M	3.4M	3.3M	2.9M	3.5M	3.2M	2.6M	2.4M	3M	2.6M
Operating margin	31.7%	32%	40.8%	33.1%	33.4%	32%	35.7%	32.1%	26.6%	27%	34.5%	31.1%
Non-operating income, net	812K	1.1M	172K	773K	836K	684K	391K	640K	698K	665K	176K	637K
Pretax income	4.8M	5M	4.8M	4.2M	4.2M	3.6M	3.9M	3.8M	3.3M	3.1M	3.2M	3.3M
Income tax	846K	731K	842K	758K	616K	712K	817K	788K	678K	540K	578K	600K
Net income	3.9M	4.3M	4M	3.5M	3.6M	2.9M	3M	3M	2.6M	2.6M	2.6M	2.7M
Net margin	31.5%	34.8%	34.9%	33.2%	35.6%	31.7%	31.3%	30.6%	26.8%	28.4%	29.9%	31.5%
EBITDA	5.8M	5M	6.1M	4.1M	4.1M	3.7M	4.5M	4M	3.4M	3.2M	4.1M	2.9M
EPS	1.08	1.18	1.09	0.98	1.02	0.87	0.92	0.94	0.82	0.81	0.82	0.84
Diluted EPS	1.08	1.18	1.09	0.98	1.02	0.86	0.92	0.94	0.82	0.8	0.82	0.84

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	274M	302.6M	309M	403.3M	307.1M	365.5M	364.7M	305.7M	205M	178.3M	236.4M
Enterprise value	247.6M	262.7M	257.9M	360.9M	255.8M	304.9M	290M	213.1M	122.3M	92.8M	148.8M
Shares outstanding	3.8M	3.7M	3.7M	3.7M	3.6M	3.7M	3.6M	3.6M	3.3M	3.2M	3.2M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	22.6	35.6	16.7	27.4	28.4	24.7	22.1	18.4	14.8	15.8	22.7
P/S	6.97	7.31	7.36	8.6	7.28	7.45	6.98	6.09	5.01	4.63	6.55
P/B	3.96	3.87	3.47	3.99	2.99	3.41	3.19	2.38	1.75	1.49	1.94
EV/EBITDA	13	12.1	12.1	14.9	12.3	11.7	11.1	10.6	9.36	8	10.4
EV/Sales	6.3	6.34	6.14	7.69	6.07	6.22	5.55	4.24	2.99	2.41	4.12
Earnings yield	4.43%	2.81%	6%	3.65%	3.52%	4.05%	4.52%	5.44%	6.77%	6.33%	4.4%
FCF yield	4.1%	5.06%	5.32%	-1.11%	6.28%	5.65%	5.57%	7.08%	7.12%	8.03%	3.74%
PEG	—	—	—	—	—	—	—	—	—	—	-2.25

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	60.3%	63.7%	62.6%	62.8%	60.6%	63%	61.6%	59.8%	59%	57.1%	55.8%
Operating margin	41.2%	45.9%	44.5%	37.6%	32.5%	38.5%	37.9%	33.4%	33.2%	29.6%	36.9%
Net margin	30.9%	20.5%	44.2%	31.4%	25.6%	30.1%	31.5%	33.1%	33.9%	29.3%	29%
ROE	17.5%	10.9%	20.9%	14.6%	10.5%	13.8%	14.4%	13%	11.8%	9.46%	8.76%
ROA	15.9%	9.17%	18.6%	13.4%	9.66%	12.8%	13.3%	12.3%	11.3%	9.21%	6.1%
ROIC	27.9%	22.2%	47.1%	24.7%	20.7%	31.5%	39.9%	38.9%	32.3%	27%	25.1%
Return on tangible assets	95.6%	29.5%	43.4%	68.7%	30.5%	28.5%	21.6%	16.9%	15.5%	12.2%	10.9%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	11.4	9.32	11.6	15.9	16.4	19.5	15.1	22.6	25.6	37.6	48.6
Quick ratio	9.9	8.32	10.5	13.9	14.8	17.8	13.6	20.5	23.3	34.6	44.3
Debt / equity	—	—	0	0	0	0	0	0	0	0	0
Debt / assets	—	—	0	0	0	0	0	0	0	0	0
Net debt / EBITDA	—	—	-2.39	-1.75	-2.46	-2.33	-2.85	-4.6	-6.33	-7.37	-6.42
Effective tax rate	26.1%	55.4%	4.65%	17.7%	22%	22.4%	20.3%	17.2%	17.4%	20%	18.6%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	10.4	11.1	11.3	12.5	11.6	13.4	14.4	13.8	12.3	12.1	11.3
EPS (basic)	3.22	2.29	4.99	3.94	2.96	4.15	5.69	4.58	4.16	3.54	3.54
EPS (diluted)	3.22	2.28	4.95	3.94	2.94	4.04	4.52	4.57	3.96	3.48	3.28
Book value per share	18.4	21	23.9	27	28.2	29.3	31.5	35.3	35.2	37.4	38.3
FCF per share	2.98	4.12	4.42	-1.2	5.29	5.65	5.6	5.96	4.38	4.49	3.6
Cash per share	7	10.7	13.7	11.4	14.2	16.7	20.7	25.6	24.9	26.9	27.5
Capex per share	0.87	0.43	0.12	0.14	0.24	0.15	0.22	—	0.01	0.12	0.12

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	8.38%	3.86%	1.1%	1.15%	2.04%	1.13%	1.55%	—	0.07%	0.96%	0.96%
Capex / operating cash flow	21%	10.1%	2.57%	2.89%	4.43%	2.69%	3.87%	—	0.16%	2.53%	2.53%
Payout ratio	32.3%	34.7%	21.7%	27.9%	38.1%	77.5%	19.2%	25.7%	30.7%	35.3%	37.6%
Dividend yield	1.43%	0.98%	1.3%	1.02%	1.34%	3.14%	0.87%	1.4%	2.08%	2.23%	1.66%

Yield

1.66%

trailing twelve months

Frequency

Quarterly

Last dividend

$0.31

ex-dividend Sep 17, 2026

Payout ratio

38%

of earnings

Dividend growth

3 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Sep 17, 2026	$0.31
Jun 17, 2026	$0.31
Mar 17, 2026	$0.31
Dec 16, 2025	$0.31

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$12.5M	$12.3M	$11.3M	$10.4M	$10M	$9.2M	$9.7M	$10M	$9.8M	$9M	$8.7M	$8.5M
YoY change	-3.47%	-9.14%	-9.42%	-19.2%	-20%	-25.7%	-14.4%	-4.3%	-1.93%	-1.23%	-10.2%	-14.3%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	26.4M	40M	51.1M	42.8M	51.6M	61M	75.1M	92.9M	83M	85.8M
Receivables	3.3M	3.7M	4.1M	4.8M	4.2M	5.3M	5.5M	3.5M	4.2M	4M
Inventory	4.5M	5.2M	5.4M	6.9M	6.2M	6.6M	8.8M	9.6M	8.8M	7.9M
Total current assets	34.5M	49.2M	60.9M	54.9M	62.3M	73.2M	89.9M	106.3M	96.3M	97.7M
Property, plant & equipment	-948K	-3.7M	-3.4M	-3.2M	-3.2M	-3.1M	-3.4M	-3.4M	-3.8M	-4.5M
Goodwill & intangibles	63.5M	63.9M	57M	88.3M	76.3M	63.7M	47.5M	37.3M	32.9M	29.8M
Total assets	76.2M	92.7M	99.8M	109.8M	111.7M	115.6M	123.9M	135.5M	122.5M	122.5M
Accounts payable	906K	934K	975K	1.1M	788K	761K	1.2M	769K	696K	911K
Short-term debt	—	—	—	—	—	—	—	—	—	—
Total current liabilities	3M	5.3M	5.3M	3.4M	3.8M	3.7M	6M	4.7M	3.8M	2.6M
Long-term debt	—	—	0	376K	335K	396K	341K	295K	282K	225K
Total liabilities	6.9M	14.6M	10.8M	8.7M	8.9M	8.5M	9.6M	7.1M	5.1M	3.3M
Shareholders' equity	69.2M	78.1M	89M	101.1M	102.8M	107.1M	114.3M	128.3M	117.4M	119.3M
Total debt	—	—	0	376K	335K	396K	341K	295K	282K	225K
Net debt	—	—	-51.1M	-42.4M	-51.3M	-60.6M	-74.7M	-92.6M	-82.7M	-85.5M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	88.2M	92.9M	93.8M	89.2M	88.5M	83M	83.3M	82.2M	84.3M	85.8M	87.4M	87.5M
Receivables	3.5M	3.5M	3.6M	3.7M	3.7M	4.2M	3.9M	3.6M	3.7M	4M	3.6M	3.6M
Inventory	9.7M	9.6M	9.2M	9.1M	9.1M	8.8M	8.6M	8.2M	8.1M	7.9M	8.7M	9M
Total current assets	101.8M	106.3M	107.1M	102.3M	101.7M	96.3M	96.4M	94.4M	96.5M	97.7M	100.4M	100.6M
Property, plant & equipment	—	-3.4M	10.3M	10.2M	10.4M	-3.8M	—	—	—	-4.5M	—	—
Goodwill & intangibles	38.1M	37.3M	36.1M	35M	35.2M	32.9M	32.4M	32.3M	30.9M	29.8M	28.6M	28.6M
Total assets	131.2M	135.5M	135.4M	130M	129.7M	122.5M	122.5M	120.8M	122M	122.5M	124.4M	124.6M
Accounts payable	511K	769K	998K	834K	999K	696K	914K	737K	768K	911K	1.2M	876K
Short-term debt	—	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	4.2M	4.7M	5.5M	3.9M	3.4M	3.8M	4.3M	2.3M	3M	2.6M	3.5M	2.1M
Long-term debt	305K	295K	285K	275K	299K	282K	269K	256K	241K	225K	210K	195K
Total liabilities	7.5M	7.1M	7.7M	6M	5.5M	5.1M	5.5M	3.3M	3.7M	3.3M	4M	2.5M
Shareholders' equity	123.7M	128.3M	127.7M	124.1M	124.2M	117.4M	117M	117.5M	118.3M	119.3M	120.4M	122M
Total debt	305K	295K	285K	275K	299K	282K	269K	256K	241K	225K	210K	195K
Net debt	-87.9M	-92.6M	-93.5M	-88.9M	-88.2M	-82.7M	-83.1M	-81.9M	-84M	-85.5M	-87.2M	-87.3M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	12.1M	8.5M	18.6M	14.7M	10.8M	14.8M	16.5M	16.6M	13.9M	11.3M
Depreciation & amortization	2.8M	2.8M	3M	6.9M	7.2M	7.3M	7.1M	6.4M	2.8M	3M
Stock-based compensation	92K	129K	64K	113K	160K	166K	183K	225K	256K	373K
Change in working capital	1.1M	5.1M	-3.4M	-2.7M	1.3M	-1.6M	-2.4M	1.1M	-267K	1.7M
Operating cash flow	15.7M	15.8M	17.9M	18.7M	19.4M	20.5M	20.9M	23.7M	16.4M	14.7M
Capital expenditure	-3.3M	-1.6M	460K	-540K	-860K	-552K	-809K	—	27K	-371K
Investing cash flow	-3.3M	-1.6M	534K	-540K	-860K	-552K	-809K	—	27K	-371K
Dividends paid	-3.9M	-3M	-4M	-4.1M	-4.1M	-11.5M	-3.2M	-4.3M	-4.3M	-4M
Share repurchases	-2.9M	0	-1.2M	-398K	-7M	0	-2.5M	0	-20M	-8.4M
Financing cash flow	-6.7M	-3M	-5.2M	-4.5M	-11.1M	-11.5M	-5.7M	-4.3M	-24.2M	-12.3M
Net change in cash	5.7M	11.3M	13.2M	13.6M	7.5M	8.5M	14.5M	19.4M	-7.8M	2M
Free cash flow	11.2M	15.3M	16.4M	-4.5M	19.3M	20.7M	20.3M	21.6M	14.6M	14.3M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	3.9M	4.3M	4M	3.5M	3.6M	2.9M	3M	3M	2.6M	2.6M	2.6M	2.7M
Depreciation & amortization	1.8M	1M	683K	693K	740K	730K	721K	758K	769K	760K	688K	241K
Stock-based compensation	53K	72K	79K	52K	53K	72K	82K	86K	94K	111K	120K	72K
Change in working capital	-417K	648K	287K	-77K	221K	-698K	504K	850K	-373K	758K	-676K	-544K
Operating cash flow	5.2M	5.6M	4.8M	4M	4.5M	3.1M	4.1M	4.6M	3.9M	3.5M	3.1M	1.4M
Capital expenditure	0	—	27K	0	0	0	0	184K	—	—	—	—
Investing cash flow	0	—	27K	0	0	0	0	184K	—	—	—	—
Dividends paid	-1.1M	-1.1M	-1.1M	-1.1M	-1.1M	-1M	-1M	-1M	-988K	-977K	-989K	-987K
Share repurchases	0	0	-3M	-6.4M	-3.9M	-6.7M	-3.2M	-3.5M	-653K	-994K	-128K	-78K
Financing cash flow	-1.1M	-1.1M	-4.1M	-7.5M	-4.9M	-7.7M	-4.2M	-4.5M	-1.6M	-2M	-1.1M	-1.1M
Net change in cash	4.1M	4.6M	770K	-3.5M	-394K	-4.7M	-99K	287K	2.2M	1.5M	2M	318K
Free cash flow	4.9M	5.2M	5.3M	2.6M	3.8M	2.9M	4.3M	2.8M	3.9M	3.4M	3M	1.2M

Utah Medical Products Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement